These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33522410)

  • 1. DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice.
    Nistala R; Meuth AI; Smith C; An J; Habibi J; Hayden MR; Johnson M; Aroor A; Whaley-Connell A; Sowers JR; McKarns SC; Bender SB
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F505-F517. PubMed ID: 33522410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II-Induced Cardiac Diastolic Dysfunction in Male Mice.
    Brown SM; Smith CE; Meuth AI; Khan M; Aroor AR; Cleeton HM; Meininger GA; Sowers JR; DeMarco VG; Chandrasekar B; Nistala R; Bender SB
    Endocrinology; 2017 Oct; 158(10):3592-3604. PubMed ID: 28977602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules.
    Aroor A; Zuberek M; Duta C; Meuth A; Sowers JR; Whaley-Connell A; Nistala R
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition.
    Nistala R; Habibi J; Lastra G; Manrique C; Aroor AR; Hayden MR; Garro M; Meuth A; Johnson M; Whaley-Connell A; Sowers JR
    Endocrinology; 2014 Jun; 155(6):2266-76. PubMed ID: 24712875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
    Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
    Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD.
    Benetti A; Martins FL; Sene LB; Shimizu MHM; Seguro AC; Luchi WM; Girardi ACC
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F285-F296. PubMed ID: 33346727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.
    Nistala R; Savin V
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F661-F670. PubMed ID: 28122713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
    Beraldo JI; Benetti A; Borges-Júnior FA; Arruda-Junior DF; Martins FL; Jensen L; Dariolli R; Shimizu MH; Seguro AC; Luchi WM; Girardi ACC
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menopause and FOXP3
    Pollow DP; Uhlorn JA; Sylvester MA; Romero-Aleshire MJ; Uhrlaub JL; Lindsey ML; Nikolich-Zugich J; Brooks HL
    Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H415-H423. PubMed ID: 31099612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
    Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
    Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
    Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
    Jang JH; Janker F; De Meester I; Arni S; Borgeaud N; Yamada Y; Gil Bazo I; Weder W; Jungraithmayr W
    Carcinogenesis; 2019 Apr; 40(2):324-334. PubMed ID: 30698677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bidirectional relation between dipeptidyl peptidase 4 and angiotensin II type I receptor signaling.
    Martins FL; Ribeiro-Silva JC; Nistala R; Girardi ACC
    Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1203-C1211. PubMed ID: 38581656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proximal Tubule-Specific Deletion of the NHE3 (Na
    Li XC; Zhu D; Chen X; Zheng X; Zhao C; Zhang J; Soleimani M; Rubera I; Tauc M; Zhou X; Zhuo JL
    Hypertension; 2019 Sep; 74(3):526-535. PubMed ID: 31352824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chemokine receptor CX
    Ahadzadeh E; Rosendahl A; Czesla D; Steffens P; Prüßner L; Meyer-Schwesinger C; Wanner N; Paust HJ; Huber TB; Stahl RAK; Wiech T; Kurts C; Seniuk A; Ehmke H; Wenzel UO
    Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1526-F1535. PubMed ID: 30207169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
    Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
    Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension.
    Kobori H; Prieto-Carrasquero MC; Ozawa Y; Navar LG
    Hypertension; 2004 May; 43(5):1126-32. PubMed ID: 15037565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.